Tuberculosis

Li, Y., Regan, M., Barham, T., Beeler Asay, G., Cohen, T., Hill, A., Horsburgh, C., Miller, J., Khan, A., Marks, S., Myles, R., Salomon, J., Self, J., & Menzies, N. (2024). Disparities in tuberculosis incidence by race and ethnicity among the U.S.-born population in the United States, 2011 to 2021: An analysis of national disease registry data. Annals of Internal Medicine. https://doi.org/10.7326/M23-2975

Ekramnia, M., Li, Y., Haddad, M., Marks, S., Kammerer, J., Swartwood, N., Cohen, T., Miller, J., Horsburgh, C., Salomon, J., & Menzies, N. (2024). Estimated rates of progression to tuberculosis disease for persons infected with Mycobacterium tuberculosis in the United States. Epidemiology, 35(2), 164-173. https://doi.org/10.1097/EDE.0000000000001707

Regan, M., Li, Y., Swartwood, N., Barham, T., Beeler Asay, G., Cohen, T., Hill, A., Horsburgh, C., Khan, A., Marks, S., Myles, R., Salomon, J., Self, J., & Menzies, N. (2024). Racial and ethnic disparities in diagnosis and treatment outcomes among US-born people diagnosed with tuberculosis, 2003–19: An analysis of national surveillance data. The Lancet Public Health, 9(1), e47-e56. https://doi.org/10.1016/S2468-2667(23)00276-1

Swartwood, N., Testa, C., Cohen, T., Marks, S., Hill, A., Asay, G., Cochran, J., Cranston, K., Randall, L., Tibbs, A., Horsburgh, C., Salomon, J., & Menzies, N. (2023). Tabby2: A user-friendly web tool for forecasting state-level TB outcomes in the United States. BMC Medicine, 21(331). https://doi.org/10.1186/s12916-023-02785-y

Kim, S., Cohen, T., Horsburgh, C., Miller, J., Hill, A., Marks, S., Li, R., Kammerer, J., Salomon, J., & Menzies, N. (2022). Trends, mechanisms, and racial/ethnic differences of tuberculosis incidence in the US-born population aged 50 years or older in the United States. Clinical Infectious Diseases, 74(9), 1594–1603. https://doi.org/10.1093/cid/ciab668

Menzies, N., Shrestha, S., Parriott, A., Marks, S., Hill, A., Dowdy, D., Shete, P., Cohen, T., & Salomon, J. (2022). The health and economic benefits of tests that predict future progression to tuberculosis disease. Epidemiology, 33(1), 75-83. https://doi.org/10.1097/EDE.0000000000001418

Menzies, N., Swartwood, N., Testa, C., Malyuta, Y., Hill, A., Marks, S., Cohen, T., & Salomon, J. (2021). Time since infection and risks of future disease for individuals with mycobacterium tuberculosis infection in the United States. Epidemiology, 32(1), 70-78. https://doi.org/10.1097/EDE.0000000000001271

Menzies, N., Parriott, A., Shrestha, S., Dowdy, D., Cohen, T., Salomon, J., Marks, S., Hill, A., Winston, C., Asay, G., Barry, P., Readhead, A., Flood, J., Kahn, J., & Shete, P. (2020). Comparative modeling of tuberculosis epidemiology and policy outcomes in California. American Journal of Respiratory and Critical Care Medicine, 201(3), 356-365. https://doi.org/10.1164/rccm.201907-1289OC

Shrestha, S., Parriott, A., Menzies, N., Shete, P., Hill, A., Marks, S., & Dowdy, D. (2020). Estimated population-level impact of using a six-week regimen of daily Rifapentine to treat latent tuberculosis infection in the United States. Annals of the American Thoracic Society, 17(12), 1639-1642. https://doi.org/10.1513/AnnalsATS.202005-574RL

Hill, A., Cohen, T., Salomon, J., & Menzies, N. (2020). High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000-2016. Epidemics, 33. https://doi.org/10.1016/j.epidem.2020.100419

Menzies, N., Bellerose, M., Testa, C., Swartwood, N., Malyuta, Y., Cohen, T., Marks, S., Hill, A., Date, A., Maloney, S., Bowden, S., Grills, A., & Salomon, J. (2020). Impact of effective global tuberculosis control on health and economic outcomes in the United States. American Journal of Respiratory and Critical Care Medicine, 202(11), 1567-1575. https://doi.org/10.1164/rccm.202003-0526OC

Marks, S., Dowdy, D., Menzies, N., Shete, P., Salomon, J., Parriott, A., Shrestha, S., Flood, J., & Hill, A. (2020). Policy implications of mathematical modeling of latent tuberculosis infection testing and treatment strategies to accelerate tuberculosis elimination. Public Health Reports, 135, 38S-43S. https://doi.org/10.1177/0033354920912710

Menzies, N., Cohen, T., & Salomon, J. (2018). Evidence sources on the natural history of latent tuberculosis infection. Lancet Infectious Diseases, 18(8), 834-835. https://doi.org/10.1016/S1473-3099(18)30406-7

Menzies, N., Wolf, E., Connors, D., Bellerose, M., Sbarra, A., Cohen, T., Hill, A., Yaesoubi, R., Galer, K., White, P., Abubakar, I., & Salomon, J. (2018). Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infectious Diseases, 18(8), e228-e238. https://doi.org/10.1016/S1473-3099(18)30134-8

Menzies, N., Cohen, T., Hill, A., Yaesoubi, R., Galer, K., Wolf, E., Marks, S., & Salomon, J. (2018). Prospects for tuberculosis elimination in the United States: Results of a transmission dynamic model. American Journal of Epidemiology, 187(9), 2011-2020. https://doi.org/10.1093/aje/kwy094

Menzies, N., Hill, A., Cohen, T., & Salomon, J. (2018). The impact of migration on tuberculosis in the United States. International Journal of Tuberculosis and Lung Disease, 22(12), 1392-1403. https://doi.org/10.5588/ijtld.17.0185

Tasillo, A., Salomon, J., Trikalinos, T., Horsburgh, C., Marks, S., & Linas, B. (2017). Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the United States with and without medical comorbidities in a simulation model. JAMA Internal Medicine, 177(12), 1755-1764. https://doi.org/10.1001/jamainternmed.2017.3941